Literature DB >> 29799310

Clinical and imaging progression over 10 years in a patient with primary progressive apraxia of speech and autopsy-confirmed corticobasal degeneration.

Katerina A Tetzloff1, Joseph R Duffy2, Edythe A Strand2, Mary M Machulda3, Sarah M Boland2, Rene L Utianski2, Hugo Botha2, Matthew L Senjem1,4, Christopher G Schwarz1, Keith A Josephs2, Jennifer L Whitwell1.   

Abstract

Primary progressive apraxia of speech (PPAOS) is a neurodegenerative disorder in which AOS is the sole presenting complaint. We report clinical and neuroimaging data spanning 10 years from disease onset-to-death in a 49 year-old male PPAOS patient, DY, who died with corticobasal degeneration. He presented with AOS with normal neuroimaging. Abnormalities in the caudate nucleus, supplementary motor area, cingulate, insula, and Broca's area were observed after five years, with involvement of motor cortex and development of agrammatism, Parkinsonism, and dysarthria three years later. Cognitive impairment and temporoparietal atrophy were late features. This data provides important insight into disease progression of corticobasal degeneration when presenting as PPAOS.

Entities:  

Keywords:  Apraxia of speech; FDG-PET; MRI; corticobasal degeneration; longitudinal

Mesh:

Year:  2018        PMID: 29799310      PMCID: PMC6095655          DOI: 10.1080/13554794.2018.1477963

Source DB:  PubMed          Journal:  Neurocase        ISSN: 1355-4794            Impact factor:   0.881


  35 in total

1.  Clinical correlates of white matter tract degeneration in progressive supranuclear palsy.

Authors:  Jennifer L Whitwell; Ankit V Master; Ramesh Avula; Kejal Kantarci; Scott D Eggers; Heidi A Edmonson; Clifford R Jack; Keith A Josephs
Journal:  Arch Neurol       Date:  2011-06

2.  Clinical and imaging characterization of progressive spastic dysarthria.

Authors:  H M Clark; J R Duffy; J L Whitwell; J E Ahlskog; E J Sorenson; K A Josephs
Journal:  Eur J Neurol       Date:  2013-09-19       Impact factor: 6.089

3.  Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.

Authors:  K A Josephs; B F Boeve; J R Duffy; G E Smith; D S Knopman; J E Parisi; R C Petersen; D W Dickson
Journal:  Neurocase       Date:  2005-08       Impact factor: 0.881

4.  Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report.

Authors:  Maria Luisa Gorno-Tempini; Ryan C Murray; Katherine P Rankin; Michael W Weiner; Bruce L Miller
Journal:  Neurocase       Date:  2004-12       Impact factor: 0.881

5.  Primary progressive apraxia of speech: clinical features and acoustic and neurologic correlates.

Authors:  Joseph R Duffy; Edythe A Strand; Heather Clark; Mary Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Am J Speech Lang Pathol       Date:  2015-05       Impact factor: 2.408

6.  An empirically derived short form of the Boston naming test.

Authors:  A E Lansing; R J Ivnik; C M Cullum; C Randolph
Journal:  Arch Clin Neuropsychol       Date:  1999-08       Impact factor: 2.813

7.  Prediction of pathology in primary progressive language and speech disorders.

Authors:  V Deramecourt; F Lebert; B Debachy; M A Mackowiak-Cordoliani; S Bombois; O Kerdraon; L Buée; C-A Maurage; F Pasquier
Journal:  Neurology       Date:  2009-11-25       Impact factor: 9.910

8.  Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech.

Authors:  Hugo Botha; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Neurology       Date:  2014-04-11       Impact factor: 9.910

9.  FDG-PET in pathologically confirmed spontaneous 4R-tauopathy variants.

Authors:  Nicholas Zalewski; Hugo Botha; Jennifer L Whitwell; Val Lowe; Dennis W Dickson; Keith A Josephs
Journal:  J Neurol       Date:  2014-02-04       Impact factor: 4.849

10.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria.

Authors:  Günter U Höglinger; Gesine Respondek; Maria Stamelou; Carolin Kurz; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Christer Nilsson; Jennifer L Whitwell; Thomas Arzberger; Elisabet Englund; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Yaroslau Compta; Jean-Christophe Corvol; Carlo Colosimo; Dennis W Dickson; Richard Dodel; Leslie Ferguson; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw R Morris; Peter Nestor; Wolfgang H Oertel; Werner Poewe; Gil Rabinovici; James B Rowe; Gerard D Schellenberg; Klaus Seppi; Thilo van Eimeren; Gregor K Wenning; Adam L Boxer; Lawrence I Golbe; Irene Litvan
Journal:  Mov Disord       Date:  2017-05-03       Impact factor: 10.338

View more
  12 in total

Review 1.  Nuclear Imaging in the Diagnosis of Clinically Uncertain Parkinsonian Syndromes.

Authors:  Ralph Buchert; Carsten Buhmann; Ivayla Apostolova; Philipp T Meyer; Jürgen Gallinat
Journal:  Dtsch Arztebl Int       Date:  2019-11-01       Impact factor: 5.594

Review 2.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

3.  Ioflupane 123I (DAT scan) SPECT identifies dopamine receptor dysfunction early in the disease course in progressive apraxia of speech.

Authors:  Zeynep Idil Seckin; Jennifer L Whitwell; Rene L Utianski; Hugo Botha; Farwa Ali; Joseph R Duffy; Heather M Clark; Mary M Machulda; Lennon G Jordan; Hoon-Ki Min; Val J Lowe; Keith A Josephs
Journal:  J Neurol       Date:  2020-05-09       Impact factor: 4.849

4.  Autopsy Validation of Progressive Supranuclear Palsy-Predominant Speech/Language Disorder Criteria.

Authors:  Fatma Ozlem Hokelekli; Joseph R Duffy; Heather M Clark; Rene L Utianski; Hugo Botha; Farwa Ali; Julie A Stierwalt; Mary M Machulda; R Ross Reichard; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs
Journal:  Mov Disord       Date:  2021-10-10       Impact factor: 10.338

5.  The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study.

Authors:  Zeynep Idil Seckin; Joseph R Duffy; Edythe A Strand; Heather M Clark; Rene L Utianski; Mary M Machulda; Hugo Botha; Farwa Ali; Nha Trang Thu Pham; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2020-10-07       Impact factor: 4.891

6.  Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech.

Authors:  Rene L Utianski; Peter R Martin; Hugo Botha; Christopher G Schwarz; Joseph R Duffy; Ronald C Petersen; David S Knopman; Heather M Clark; Alissa M Butts; Mary M Machulda; Clifford R Jack; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Cortex       Date:  2019-11-19       Impact factor: 4.027

7.  An Evaluation of the Progressive Supranuclear Palsy Speech/Language Variant.

Authors:  Jennifer L Whitwell; Chase A Stevens; Joseph R Duffy; Heather M Clark; Mary M Machulda; Edythe A Strand; Peter R Martin; Rene L Utianski; Hugo Botha; Anthony J Spychalla; Matthew L Senjem; Christopher G Schwarz; Clifford R Jack; Farwa Ali; Anhar Hassan; Keith A Josephs
Journal:  Mov Disord Clin Pract       Date:  2019-05-29

8.  Primary Progressive Apraxia of Speech: From Recognition to Diagnosis and Care.

Authors:  Joseph R Duffy; Rene L Utianski; Keith A Josephs
Journal:  Aphasiology       Date:  2020-07-07       Impact factor: 2.773

9.  Progressive apraxia of speech: delays to diagnosis and rates of alternative diagnoses.

Authors:  Johnny Dang; Jonathan Graff-Radford; Joseph R Duffy; Rene L Utianski; Heather M Clark; Julie A Stierwalt; Jennifer L Whitwell; Keith A Josephs; Hugo Botha
Journal:  J Neurol       Date:  2021-05-04       Impact factor: 4.849

10.  A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Heather M Clark; Rene L Utianski; Edythe A Strand; Mary M Machulda; Hugo Botha; Peter R Martin; Nha Trang Thu Pham; Julie Stierwalt; Farwa Ali; Marina Buciuc; Matthew Baker; Cristhoper H Fernandez De Castro; Anthony J Spychalla; Christopher G Schwarz; Robert I Reid; Matthew L Senjem; Clifford R Jack; Val J Lowe; Eileen H Bigio; Ross R Reichard; Eric J Polley; Nilufer Ertekin-Taner; Rosa Rademakers; Michael A DeTure; Owen A Ross; Dennis W Dickson; Jennifer L Whitwell
Journal:  Nat Commun       Date:  2021-06-08       Impact factor: 17.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.